Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody

References

• Kalden JR, Burkhardt H. Autoimmune disease: Treatment. Encyclopedia of Life Sciences 2009; https://doi.org/10.1002/9780470015902.a0001437.pub2
   Google Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: An update. BMC Med 2013; 11:88; PMID: 23557513; https://doi.org/10.1186/1741-7015-11-88
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID: 20414204; https://doi.org/10.1038/nri2761
   PubMed Web of Science ®Google Scholar
• Wang D, Li Y, Liu Y, Shi G. The use of biologic therapies in the treatment of rheumatoid arthritis. Curr Pharm Biotechnol 2014; 15:542-8; PMID: 25213363; https://doi.org/10.2174/138920101506140910150612
   PubMed Web of Science ®Google Scholar
• Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: Differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord 2015; 8:274-93; PMID: 26600872; https://doi.org/10.1177/1756285615605429
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID: 20159773; https://doi.org/10.1093/protein/gzq009
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. mAbs 2011; 3:243-52; PMID: 21406966; https://doi.org/10.4161/mabs.3.3.15234
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7; PMID: 20953198; https://doi.org/10.1038/nbt.1691
   PubMed Web of Science ®Google Scholar
• Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, Hironiwa N, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PloS one 2013; 8:(5):e63236; PMID:23667591; https://doi.org/10.1371/journal.pone.0063236
   Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID: 16793771; https://doi.org/10.1074/jbc.M604292200
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9; PMID: 20081867; https://doi.org/10.1038/nbt.1601
   PubMed Web of Science ®Google Scholar
• Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; PMID: 20071453; https://doi.org/10.1124/dmd.109.031310
   PubMed Web of Science ®Google Scholar
• Zheng Y, Scheerens H, Davis JC, Jr., Deng R, Fischer SK, Woods C, Fielder PJ, Stefanich EG. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 2011; 89:283-90; PMID: 21191378; https://doi.org/10.1038/clpt.2010.311
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013; 57:6147-53; PMID: 24080653; https://doi.org/10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• West AP, Jr., Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 2000; 15; 39(32):9698-708; PMID: 10933786; https://doi.org/10.1021/bi000749m
   PubMed Web of Science ®Google Scholar
• Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000; 18:739-66; PMID: 10837074; https://doi.org/10.1146/annurev.immunol.18.1.739
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID: 19494290; https://doi.org/10.4049/jimmunol.0804182
   PubMed Web of Science ®Google Scholar
• Haraya K, Tachibana T, Iwayanagi Y, Maeda A, Ozeki K, Nezu J, Ishigai M, Igawa T. PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model. Drug Metab Pharmacokinet 2016; 31:123-32; PMID: 26944099; https://doi.org/10.1016/j.dmpk.2015.12.007
   PubMed Web of Science ®Google Scholar
• Igawa T, Haraya K, Hattori K. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunol Rev 2016; 270:132-51; PMID: 26864109; https://doi.org/10.1111/imr.12392
   PubMed Web of Science ®Google Scholar
• Iwayanagi Y, Igawa T, Maeda A, Haraya K, Wada NA, Shibahara N, Ohmine K, Nambu T, Nakamura G, Mimoto F, et al. Inhibitory FcgammaRIIb-Mediated soluble antigen clearance from plasma by a pH-Dependent Antigen-Binding antibody and its enhancement by Fc engineering. J Immunol 2015; 195:3198-205; PMID: 26320252; https://doi.org/10.4049/jimmunol.1401470
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers 2013; 35:727-34; PMID: 24324289; https://doi.org/10.1155/2013/726598
   PubMed Web of Science ®Google Scholar
• Newkirk MM. Rheumatoid factors: Host Resistance or Autoimmunity?. Clin Immunol 2002; 104:1-13; PMID: 12139942; https://doi.org/10.1006/clim.2002.5210
   PubMed Web of Science ®Google Scholar
• Carson DA, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest 1991; 87:379-83; PMID: 1991824; https://doi.org/10.1172/JCI115007
   PubMed Web of Science ®Google Scholar
• Araujo J, Zocher M, Wallace K, Peng K, Fischer SK. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. J Pharm Biomed Anal 2011; 55:1041-9; PMID: 21466939; https://doi.org/10.1016/j.jpba.2011.03.008
   PubMed Web of Science ®Google Scholar
• Sasso EH, Barber CV, Nardella FA, Yount WJ, Mannik M. Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C gamma 2-C gamma 3 interface region contains the major determinants. J Immunol 1988; 140:3098-107; PMID: 2452199
   PubMed Web of Science ®Google Scholar
• Artandi SE, Calame KL, Morrison SL, Bonagura VR. Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc Natl Acad Sci U S A 1992; 89:94-8; PMID: 1370358; https://doi.org/10.1073/pnas.89.1.94
   PubMed Web of Science ®Google Scholar
• Corper AL, Sohi MK, Bonagura VR, Steinitz M, Jefferis R, Feinstein A, Beale D, Taussig MJ, Sutton BJ. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997; 4:374-81; PMID: 9145108; https://doi.org/10.1038/nsb0597-374
   PubMedGoogle Scholar
• Martin WL, West AP, Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867-77; PMID: 11336709; https://doi.org/10.1016/S1097-2765(01)00230-1
   PubMed Web of Science ®Google Scholar
• Rigsby RE, Parker AB. Using the PyMOL application to reinforce visual understanding of protein structure. Biochem Mol Biol Educ 2016; 44:433-7; PMID: 27241834; https://doi.org/10.1002/bmb.20966
   PubMed Web of Science ®Google Scholar
• Kiyoshi M, Caaveiro JM, Kawai T, Tashiro S, Ide T, Asaoka Y, Hatayama K, Tsumoto K. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun 2015; 6:6866; PMID: 25925696; https://doi.org/10.1038/ncomms7866
   PubMed Web of Science ®Google Scholar
• Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, Powell MS, Tan PS, Cendron AC, Wines BD, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011; 187:3208-17; PMID: 21856937; https://doi.org/10.4049/jimmunol.1101467
   PubMed Web of Science ®Google Scholar
• Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131). Protein Eng Des Sel 2013; 26:589-98; PMID: 23744091; https://doi.org/10.1093/protein/gzt022
   PubMed Web of Science ®Google Scholar
• Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgammaRs. Mol Immunol 2014; 58:132-8; PMID: 24334029; https://doi.org/10.1016/j.molimm.2013.11.017
   PubMed Web of Science ®Google Scholar
• Krishna M, Nadler SG. Immunogenicity to Biotherapeutics - The role of Anti-drug immune complexes. Front Immunol 2016; 7:21; PMID: 26870037; https://doi.org/10.3389/fimmu.2016.00021
   PubMed Web of Science ®Google Scholar
• Tatarewicz S, Miller JM, Swanson SJ, Moxness MS. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods 2010; 357:10-6; PMID: 20347831; https://doi.org/10.1016/j.jim.2010.03.012
   PubMed Web of Science ®Google Scholar
• Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, Pasquali JL, Sebbag M, Serre G. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann Rheum Dis 2015; 74:1425-31; PMID: 24618262; https://doi.org/10.1136/annrheumdis-2013-204543
   PubMed Web of Science ®Google Scholar
• Jones JD, Shyu I, Newkirk MM, Rigby WF. A rheumatoid factor paradox: inhibition of rituximab effector function. Arthritis Res Ther 2013; 15(1):R20; ; PMID: 23351360; https://doi.org/10.1186/ar4152
   PubMed Web of Science ®Google Scholar
• Zhou J, Pop L, Ghetie V. Hypercatabolism of IgG in mice with lupus-like syndrome. Lupus 2005; 14:458-66; PMID: 16038110; https://doi.org/10.1191/0961203305lu2129oa
   PubMed Web of Science ®Google Scholar
• Duquerroy S, Stura EA, Bressanelli S, Fabiane SM, Vaney MC, Beale D, Hamon M, Casali P, Rey FA, Sutton BJ, et al. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol 2007; 368:1321-31; PMID: 17395205; https://doi.org/10.1016/j.jmb.2007.02.085
   PubMed Web of Science ®Google Scholar
• Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 2010; 23:643-51; PMID: 20543007; https://doi.org/10.1093/protein/gzq037
   PubMed Web of Science ®Google Scholar
• Suzuki S, Furuhashi M, Suganuma N. Additional N-glycosylation at Asn13 rescues the human LHb-subunit from disulfide-linked aggregation. Mol Cell Endocrinol 2000; 160:157-63; PMID: 10715549; https://doi.org/10.1016/S0303-7207(99)00213-0
   PubMed Web of Science ®Google Scholar
• Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol 2007; 81:1821-37; PMID: 17151111; https://doi.org/10.1128/JVI.02098-06
   PubMed Web of Science ®Google Scholar
• Wang W, Lu B, Zhou H, Suguitan AL, Jr., Cheng X, Subbarao K, Kemble G, Jin H. Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. J Virol 2010; 84:6570-7; PMID: 20427525; https://doi.org/10.1128/JVI.00221-10
   PubMed Web of Science ®Google Scholar
• Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchauspe G. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol 2001; 75:12088-97; PMID: 11711599; https://doi.org/10.1128/JVI.75.24.12088-12097.2001
   PubMed Web of Science ®Google Scholar
• Hutter J, Rodig JV, Hoper D, Seeberger PH, Reichl U, Rapp E, Lepenies B. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity. J Immunol 2013; 190:220-30; PMID: 23225881; https://doi.org/10.4049/jimmunol.1201060
   PubMed Web of Science ®Google Scholar
• Hyakumura M, Walsh R, Thaysen-Andersen M, Kingston NJ, La M, Lu L, Lovrecz G, Packer NH, Locarnini S, Netter HJ. Modification of Asparagine-Linked glycan density for the design of Hepatitis B Virus Virus-Like particles with enhanced immunogenicity. J Virol 2015; 89:11312-22; PMID: 26339047; https://doi.org/10.1128/JVI.01123-15
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganesyan V, Dall'Acqua WF, Tsui P. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem 2015; 290:4282-90; PMID: 25538249; https://doi.org/10.1074/jbc.M114.603712
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 2012; 40:1545-55; PMID: 22584253; https://doi.org/10.1124/dmd.112.045864
   PubMed Web of Science ®Google Scholar
• Ng CM, Loyet KM, Iyer S, Fielder PJ, Deng R. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-alpha IgG antibody in cynomolgus monkey. Eur J Pharm Sci 2014; 51:51-8; PMID: 23999033; https://doi.org/10.1016/j.ejps.2013.08.033
   PubMed Web of Science ®Google Scholar
• De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131:189-201; PMID: 19269256; https://doi.org/10.1016/j.clim.2009.01.009
   PubMed Web of Science ®Google Scholar
• Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol 2013; 149:534-55; PMID: 24263283; https://doi.org/10.1016/j.clim.2013.09.006
   PubMed Web of Science ®Google Scholar
• Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 2010; 137:5-14; PMID: 20708973; https://doi.org/10.1016/j.clim.2010.06.018
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 2010; 602:93-104; PMID: 20012394
   PubMedGoogle Scholar
• Rashid A, Auchincloss H Jr., Sharon J. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice. J Immunol 1992; 148:1382-8
   PubMed Web of Science ®Google Scholar